Neotherix is pleased to announce that Dr Mike Raxworthy, the company's founder and Chief Executive Officer, will be presenting at the 8th annual conference on Commercial Translation of Regenerative Medicine on 18-19 November at the Hilton Kensington, London.
Dr Raxworthy's presentation, at 16:35 on Friday 19 November, will focus on accessing translational funding for RegenMed product development and will highlight Neotherix' success in gaining project funding from the UK Technology Strategy Board for the development of its pipeline of bioresorbable tissue scaffold devices. The talk will discuss the electrospinning technology platform used to form these scaffolds and opportunities for their use in soft tissue repair. Mike Raxworthy will also discuss other opportunities for obtaining funding to progress from the research stage to translation towards the clinic and the market for regenerative therapies. Finally, some observations will be made on the outlook for accessing funding in 2011.
The Commercial Translation of Regenerative Medicine conference brings together some of the world's leading companies and experts involved in developing regenerative medicine therapies and the strategies to take these to a successful and sustainable market entry. Dr Raxworthy is delighted to be invited to participate in the meeting and to be included amongst the leading experts from industry and academia presenting on the translational barriers and advances inherent in the commercialisation of regenerative medicine.
More details of the conference can be found here .